



## New Technologies in Prostate Cancer: From Diagnosis to Treatment

Guest Editor:

**Dr. Fabio Zattoni**

1. Department of Urology,  
Azienda Ospedale-Università  
Padova, 35122 Padova, Italy  
2. Department of Medicine  
(DIMED), University of Padua,  
35128 Padova, Italy

Deadline for manuscript  
submissions:  
**closed (31 July 2022)**

### Message from the Guest Editor

Dear Colleagues,

This Special Issue aims to explore cutting-edge, new technologies that may, in the near future, be able to change the current diagnostic and treatment pathways of prostate cancer.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- Artificial intelligence;
- Radiomics;
- PET/MRI;
- New PET tracers;
- Liquid biopsy;
- New genomic markers;
- Telemedicine;
- Augmented reality;
- New and developing robotic systems;
- Single-site surgery;
- Telerobotic surgery;
- Radio-guided surgery;
- Focal therapies;
- Theragnostics.

Dr. Fabio Zattoni  
Guest Editor





an Open Access Journal by MDPI

## Editor-in-Chief

**Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)